Rocket Pharmaceuticals Pulls FDA Application for RP-L102 Gene Therapy
By Colin Kellaher
Rocket Pharmaceuticals has withdrawn its application seeking Food and Drug Administration approval of its RP-L102 proposed gene therapy for the treatment of the rare, inherited blood disorder Fanconi anemia.
Rocket on Friday said the move follows the reorganization and pipeline prioritization the biotechnology company announced in July that included a 30% reduction in its workforce.
The Cranbury, N.J., company in July said it would focus its resources on programs with the clearest regulatory and commercial pathways, and that it no longer expected FDA approval of RP-L102 in 2026.
Rocket, which previously ceased new internal investment in RP-L102 and withdrew its European marketing authorization application, said it will consider external partnership opportunities that could enable the advancement of RP-L102 in the future.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 03, 2025 08:08 ET (12:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States